Pharmacists' role in buprenorphine management for opioid use disorder: A narrative review

被引:7
|
作者
Cleary, Jacqueline [1 ]
Engle, Amanda [1 ]
Winans, Amanda [2 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Albany, NY USA
[2] Bassett Med Ctr, Cooperstown, NY USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2022年 / 5卷 / 02期
关键词
buprenorphine; collaborative care model; collaborative practice model; opioid use disorder; pharmacist; CARE;
D O I
10.1002/jac5.1579
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The continued rise in patients treated for opioid use disorder (OUD) has called for an increase in access to OUD therapies. Pharmacists, who have previously demonstrated their value in various disease states, have begun to address gaps in OUD care by facilitating buprenorphine treatment. The objective was to review current literature and characterize the pharmacists' role in buprenorphine collaborative care models for patients with OUD. PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature, and Google Scholar were queried through May 2021. Studies were included if a pharmacist was part of a care model in which buprenorphine was prescribed for OUD and excluded if there was a pain management indication, a limited pharmacist role, or a survey methodology was used. Eight care models were included in this review. Key characteristics identified were (1) pharmacist role, (2) collaborating prescriber type, (3) clinic setting, (4) pharmacist practice type, and (5) outcomes. All models were located within a variety of outpatient settings. No collaborative practice model involved autonomous buprenorphine prescriptive authority by pharmacists. The majority utilized a psychiatrist as a collaborating prescriber, alongside a psychiatry-trained pharmacist. Less than half utilized pharmacists to make dosing recommendations. Outcomes evaluating treatment retention and relapse rates were most reported. Most outcomes identified across each model were either improved or unchanged by pharmacist involvement. Pharmacists are valued members of buprenorphine care teams across a variety of settings, collaborate with various clinicians, and have a positive impact on patient outcomes such as treatment retention and relapse. Few published collaborative care models exist, suggesting pharmacists may be underutilized in caring for this growing patient population. The role of the pharmacist in buprenorphine management is not currently well-defined; however, pharmacists are well prepared to take a more active role to help address the opioid crisis.
引用
收藏
页码:228 / 238
页数:11
相关论文
共 50 条
  • [31] Polysubstance Use in Adults With Opioid Use Disorder Receiving Buprenorphine Maintenance
    Elarabi, Hesham Farouk
    Radwan, Doaa Nader
    Adem, Abdu
    Marsden, John
    Lee, Amanda J.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (01) : 74 - 78
  • [32] Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder
    Chang, Hsien-Yen
    Daubresse, Matthew
    Saloner, Brendan
    Alexander, G. Caleb
    MEDICAL CARE, 2019, 57 (09) : 667 - 672
  • [33] Role of the pharmacist in acute care interventions for opioid use disorder: A scoping review
    Irwin, Madison N.
    Walkerly, Autumn
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2022, 5 (02): : 193 - 202
  • [34] Nurses' Practices With Persons Experiencing Opioid Use Disorder A Narrative Literature Review
    Sowicz, Timothy Joseph
    Huneycutt, Brittany
    Lee, Jung Min
    JOURNAL OF ADDICTIONS NURSING, 2022, 33 (01) : 3 - 12
  • [35] Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
    Kanervo, Minna M.
    Tupola, Sarimari J.
    Nikkola, Eeva M.
    Rantakari, Krista M.
    Kahila, Hanna K.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2023, 102 (03) : 313 - 322
  • [36] Disparities in Buprenorphine Administration for Opioid Use Disorder in the Emergency Department
    Koerber, Samantha N.
    Huynh, David
    Farrington, Sydney
    Springer, Kylie
    Manteuffel, Jacob
    JOURNAL OF ADDICTION MEDICINE, 2025, 19 (01) : 89 - 94
  • [37] Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder
    Wyse, Jessica J.
    Eckhardt, Alison
    Waller, Dylan
    Gordon, Adam J.
    Shull, Sarah
    Lovejoy, Travis I.
    Mackey, Katherine
    Morasco, Benjamin J.
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (03) : 300 - 305
  • [38] Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
    Anderson, Kelly E.
    Saloner, Brendan
    Eckstein, Julia
    Chaisson, Christine E.
    Scholle, Sarah H.
    Niles, Lauren
    Dy, Sydney
    Alexander, G. Caleb
    MEDICAL CARE, 2021, 59 (05) : 393 - 401
  • [39] Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
    Reed, Megan K.
    Murali, Vignesh
    Sarpoulaki, Nazanin
    Zavodnick, Jillian H.
    Hom, Jeffrey K.
    Rising, Kristin L.
    DRUG AND ALCOHOL DEPENDENCE REPORTS, 2022, 5
  • [40] Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder
    Baylis, Jacob D.
    Jorgenson, Terri L.
    Pals, Haley E.
    Hwang, Catherine S.
    Colvard, Michelle D.
    Alliu, Veldana
    Moore, Tera
    Lin, Lewei A.
    Wyse, Jessica
    Hawkins, Eric J.
    Hagedorn, Hildi J.
    Gordon, Adam J.
    DRUG AND ALCOHOL DEPENDENCE, 2025, 271